This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

35 years video thumbnail

Norditropin® is the growth hormone treatment with over 35 years of commitment to growth disorders.
Noonan syndrome thumbnail

Norditropin® is the only internationally approved growth hormone treatment indicated for growth failure due to Noonan syndrome.
Global community thumbnail

Learn how Norditropin® is partnering with the growth hormone community across the globe.

1.

Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard AM. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther. 2009;31(12):2906-2914.

2.

Concertation for Procedure No, 1. Committee for Proprietary Medicinal Products. Meeting of 13 April 1988.

For healthcare professional only

The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/or treatment guidance. This is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuraqcy, completeness or use of this information, and disclaims and liability to update the information contained on this site. By accessing this site and materials you accept this legal notice.

 

HQ23GH00008, August 2023

 

SmPC

The Summary of Product Characteristics (SmPC) is based on the EU SmPC of November 2022. Registration conditions differs from country to country. Always refer to the full local SmPC before prescribing Norditropin®. Norditropin® is registered in EU, USA, Canada, Latin America, Middle East and Asia